CD8A and cancer: As DCs ingest components of cancer cells and present their antigens to T cells in the lymph nodes where a cytotoxic CD8+ T cell can recognise them, become activated and gain the ability to destroy any cell that carries a matching antigen on its surface, this rhythmic trafficking of DCs governs the circadian anti‐tumour effects of CD8+ T cells.